Home » Biotechnology » Canada Stem Cell Contract Manufacturing Market

Canada Stem Cell Contract Manufacturing Market By Scale of Operation (Commercial, Clinical, Preclinical); By Size of Contract Manufacturer (Large/Very Large, Mid-sized, Small-sized); By Source of Stem Cells (Allogenic, Autologous); By Type of Stem Cells (Adult Stem Cells (ASCs), Human Embryonic Stem Cells (HESCs), Induced Pluripotent Stem Cells (iPSCs)); By End-user (Biopharmaceutical Companies, Research Institutes, Others) – Growth, Share, Opportunities & Competitive Analysis, 2024 – 2032

Price: $2699

Published: | Report ID: 71818 | Report Format : PDF
REPORT ATTRIBUTE DETAILS
Historical Period 2019-2022
Base Year 2023
Forecast Period 2024-2032
Canada Stem Cell Contract Manufacturing Market Size 2024 USD 78.86 million
Canada Stem Cell Contract Manufacturing Market, CAGR 11.63%
Canada Stem Cell Contract Manufacturing Market Size 2032 USD 190.17 million

Market Overview:

The Canada Stem Cell Contract Manufacturing Market is projected to grow from USD 78.86 million in 2024 to an estimated USD 190.17 million by 2032, with a compound annual growth rate (CAGR) of 11.63% from 2024 to 2032.

Market drivers for the Canada stem cell contract manufacturing industry are multifaceted. Firstly, the growing prevalence of chronic diseases such as cancer, diabetes, and cardiovascular conditions is contributing to the need for innovative therapies, including stem cell-based treatments. Additionally, stem cells’ potential in regenerative medicine, particularly in repairing damaged tissues and organs, is generating significant interest from pharmaceutical companies and biotech firms. The rising focus on personalized medicine is also a key driver, as stem cell therapies offer tailored treatment options based on individual patient profiles. Moreover, the rising number of partnerships between contract manufacturers and biotechnology companies is enhancing the scalability and efficiency of stem cell production. The regulatory environment in Canada is also supportive of stem cell research and manufacturing, which boosts market growth. However, challenges such as high production costs and the complexity of stem cell therapy manufacturing remain as obstacles.

Regionally, Canada plays a pivotal role in the North American stem cell contract manufacturing market. The country has a strong research and development infrastructure, which supports the innovation and commercialization of stem cell therapies. Key Canadian cities, including Toronto, Montreal, and Vancouver, are hubs for leading stem cell research institutes, pharmaceutical companies, and contract manufacturing organizations (CMOs). These regions benefit from a well-established healthcare system, a highly skilled workforce, and government initiatives aimed at fostering biotechnological advancements. Furthermore, the Canadian market is benefiting from increasing collaborations between local manufacturers and international companies, providing access to global expertise and technologies. While the U.S. market dominates the North American region, Canada is positioned as a significant player, particularly in stem cell research and clinical trials, contributing to the overall growth of the contract manufacturing sector.

Design Element 2

Access crucial information at unmatched prices!

Request your free sample report today & start making informed decisions powered by Credence Research!

Download Free Sample

CTA Design Element 3

Market Insights:

  • The market is projected to grow significantly, with a CAGR of 11.63% from 2024 to 2032.
  • Rising prevalence of chronic diseases, advancements in regenerative medicine, personalized medicine, industry collaborations, and a supportive regulatory environment drive market growth.
  • High manufacturing costs, regulatory and compliance hurdles, scalability and standardization issues, and a limited skilled workforce pose significant challenges.
  • Strong research and development infrastructure, a hub for stem cell research, and collaboration with international players position Canada as a key player.
  • Increasing demand for regenerative medicine fuels market growth.
  • Rising number of clinical trials creates a significant demand for manufacturing services.
  • A Supportive Regulatory Environment and Advancements in Stem Cell Technology further drive market growth.

Market Drivers:

Increasing Demand for Regenerative Medicine

One of the primary drivers of the Canada stem cell contract manufacturing market is the growing demand for regenerative medicine. Stem cell therapies hold significant promise in treating a variety of degenerative diseases, including cardiovascular diseases, diabetes, neurodegenerative disorders, and musculoskeletal injuries. For instance, companies like BioAuxilium Research are developing and manufacturing assay kits that accelerate biomedical research, which supports the production of stem cell-based products. The potential of stem cells to repair and regenerate damaged tissues and organs is propelling the interest in this field, both among healthcare providers and patients. As a result, pharmaceutical companies and biotech firms are increasingly seeking contract manufacturers with the expertise and facilities to produce stem cell-based products at scale. This demand for regenerative therapies is accelerating the need for specialized manufacturing solutions that meet the stringent regulatory requirements for stem cell production.

Rising Number of Clinical Trials

Another important driver for the growth of the stem cell contract manufacturing market in Canada is the rising number of clinical trials focused on stem cell therapies. As stem cell-based treatments progress through preclinical and clinical phases, the need for manufacturing services increases to ensure the consistency and scalability of the product. For instance, BRI Biopharmaceutical Research Inc. provides specialized analytical and bioanalytical services that support clinical programs. Canada is becoming a key location for such trials, with many research institutions and clinical centers conducting cutting-edge studies on stem cell applications. This surge in clinical trial activities is creating a significant demand for contract manufacturers who can support the production of clinical-grade stem cell materials and meet regulatory standards. The growth of clinical trials further highlights the importance of collaboration between biotechnology companies and experienced contract manufacturers, fueling market growth.

Supportive Regulatory Environment

The regulatory environment in Canada is another key driver influencing the stem cell contract manufacturing market. The Canadian government and regulatory bodies, such as Health Canada, have implemented frameworks that foster the development of innovative therapies, including stem cell-based treatments. These regulations provide clear guidelines for the clinical development and commercialization of stem cell therapies while maintaining high safety standards. For instance, CiToxLAB offers comprehensive laboratory sciences investigations, including bioanalysis and biomarkers investigations, ensuring compliance with regulatory standards. The supportive regulatory landscape not only encourages research and development in the field of regenerative medicine but also bolsters the market for contract manufacturers who provide services in compliance with these regulations. By ensuring the production of high-quality, compliant stem cell products, contract manufacturers play a crucial role in the success of stem cell-based treatments in Canada.

Advancements in Stem Cell Technology

The continuous advancements in stem cell technology are another key driver of the Canada stem cell contract manufacturing market. Breakthroughs in stem cell biology, such as improved methods for differentiation, scalability, and cell expansion, are enhancing the efficiency of stem cell production. For instance, advancements in technologies like THUNDER™ TR-FRET by BioAuxilium Research are enabling more efficient assay development. These technological advancements enable contract manufacturers to offer more cost-effective and reliable solutions for producing large volumes of stem cells for clinical and commercial use. Moreover, the development of more sophisticated tools for stem cell characterization and quality control ensures that the final products meet the required standards for safety and efficacy. As stem cell technologies continue to evolve, the demand for specialized contract manufacturing services capable of incorporating these innovations is expected to rise, driving further market growth.

Market Trends:

Increase in Strategic Partnerships

A significant trend in the Canada stem cell contract manufacturing market is the rise in strategic partnerships between biotechnology companies and contract manufacturers. As the complexity of stem cell therapy production continues to grow, many biotech firms are increasingly turning to established contract manufacturing organizations (CMOs) for specialized support. For instance, the Centre for Commercialization of Regenerative Medicine (CCRM) has partnered with various biotech firms to advance stem cell research and manufacturing capabilities. These partnerships allow for shared resources, expertise, and infrastructure, enabling biotechnology firms to focus on research and development while outsourcing manufacturing. Canadian CMOs benefit from these partnerships by expanding their service offerings, improving scalability, and enhancing their technological capabilities. Additionally, these collaborations are helping to streamline the regulatory approval process, facilitating the commercialization of stem cell-based therapies.

Integration of Automation and Digital Technologies

Another important trend shaping the Canada stem cell contract manufacturing market is the integration of automation and digital technologies. As the demand for high-quality stem cell products increases, contract manufacturers are adopting advanced technologies to improve the efficiency, consistency, and scalability of production processes. For instance, OmniaBio’s new facility in Hamilton, Ontario, employs advanced technologies such as robotics, biosensors, and machine learning to enhance manufacturing efficiency and product quality. Automation tools such as robotic systems, automated bioreactors, and digital monitoring systems are becoming more prevalent in stem cell manufacturing facilities. These technologies help reduce human error, optimize production timelines, and ensure higher yields of stem cells. The growing use of digital technologies, including artificial intelligence and machine learning, further enhances predictive capabilities in production processes, quality control, and supply chain management, making stem cell manufacturing more streamlined and cost-efficient.

Expansion of Allogeneic Stem Cell Therapies

A key market trend within the Canada stem cell contract manufacturing space is the growing focus on allogeneic stem cell therapies. Unlike autologous stem cell therapies, which use a patient’s own cells, allogeneic therapies involve stem cells from healthy donors, which can be mass-produced and stored for use in a broad patient population. For instance, the Centre for Commercialization of Regenerative Medicine (CCRM) is actively involved in developing allogeneic stem cell therapies, collaborating with various partners to enhance production capabilities. The expansion of allogeneic therapies is driving demand for large-scale manufacturing solutions that are capable of producing consistent and high-quality stem cell products in large quantities. As these therapies gain traction in the market due to their potential to treat a variety of conditions at a lower cost than autologous therapies, Canadian contract manufacturers are adapting their operations to meet the needs of this growing segment, including investments in advanced biomanufacturing technologies and facilities.

Growing Focus on Cell-Based Immunotherapies

Cell-based immunotherapies, including those utilizing stem cells, are becoming increasingly prominent in the Canadian market. With the rise of cancer immunotherapy and advancements in the use of stem cells for immunomodulation, Canadian companies are expanding their offerings in this area. For instance, the Canadian-Led Immunotherapies in Cancer (CLIC) program has shown promising results in clinical trials for CAR-T cell therapy, which involves modifying a patient’s T cells to enhance their cancer-fighting abilities. Stem cells, particularly mesenchymal stem cells (MSCs), have shown potential in modulating the immune system, thus enhancing the effectiveness of immunotherapies. The growing application of stem cells in oncology and immune system regulation is prompting contract manufacturers to enhance their capabilities in this specialized area. This trend is not only increasing demand for advanced manufacturing services but is also driving innovation within the sector, as CMOs work to meet the evolving requirements of companies developing cell-based immunotherapies. As these therapies progress through clinical trials and into commercialization, the need for high-quality and reliable stem cell manufacturing will continue to grow, further bolstering the market.

Market Challenges Analysis:

High Manufacturing Costs

One of the key restraints in the Canada stem cell contract manufacturing market is the high cost associated with the production of stem cell-based therapies. The process of producing clinical-grade stem cells involves complex and highly regulated procedures, including cell isolation, expansion, differentiation, and quality control. These processes often require specialized equipment, highly skilled personnel, and substantial investment in facilities, driving up the cost of production. As a result, stem cell therapies can be expensive to manufacture, which may hinder the widespread adoption of these treatments. Additionally, the high cost of manufacturing can limit access to these therapies, especially for smaller biotech firms with limited resources.

Regulatory and Compliance Challenges

Another significant challenge in the stem cell contract manufacturing market is navigating the complex regulatory landscape. Stem cell therapies are subject to stringent regulations to ensure their safety, efficacy, and quality. In Canada, regulatory bodies such as Health Canada impose rigorous guidelines for stem cell product development, clinical trials, and commercialization. Compliance with these regulations requires substantial investment in time, resources, and expertise. Additionally, variations in regulatory requirements across different regions can create challenges for manufacturers that aim to distribute stem cell therapies globally. Ensuring consistent compliance while meeting the evolving regulatory standards is an ongoing challenge for contract manufacturers in this sector.

Scalability and Standardization Issues

Scalability and standardization remain significant challenges in the stem cell manufacturing process. The transition from small-scale research and development to large-scale commercial production often introduces complications related to maintaining consistent cell quality, yield, and safety. Stem cells are sensitive biological materials, and minor variations in production methods can affect the quality and functionality of the final product. Ensuring that manufacturing processes are both scalable and standardized is essential to meet the growing demand for stem cell-based therapies. Achieving consistent, high-quality production at scale is a complex task that many contract manufacturers are still working to optimize.

Limited Skilled Workforce

The lack of a sufficiently skilled workforce in the field of stem cell manufacturing also presents a challenge. The production of stem cell therapies requires specialized knowledge in stem cell biology, biomanufacturing processes, and regulatory compliance. There is a limited pool of professionals with the expertise needed to manage these complex manufacturing processes, which can hinder the growth of the market. The need for skilled scientists, technicians, and regulatory experts continues to increase, but the demand often outpaces the supply of qualified personnel, creating a barrier to the expansion of the sector.

Market Opportunities:

The Canada stem cell contract manufacturing market presents significant opportunities for growth, particularly as the demand for regenerative medicine continues to rise. With stem cell therapies showing immense potential in treating a wide range of chronic and degenerative diseases, there is an increasing need for specialized manufacturing solutions. This demand is driven by the expanding pipeline of stem cell-based products and the growing number of clinical trials focused on these therapies. Contract manufacturers in Canada have the opportunity to capitalize on this trend by offering advanced production capabilities, ensuring the scalability, consistency, and regulatory compliance required for successful commercialization. By providing tailored services for both autologous and allogeneic stem cell products, manufacturers can serve a diverse range of biotechnology and pharmaceutical companies, further propelling market growth.

Moreover, the Canadian government’s support for stem cell research and the country’s strong healthcare infrastructure create a conducive environment for market expansion. With increasing investments in stem cell research and the development of regenerative therapies, Canadian contract manufacturers can leverage these advancements to develop innovative solutions and enhance their service offerings. Furthermore, there is potential for cross-border collaborations with international companies, opening up new revenue streams and facilitating knowledge exchange. As stem cell-based immunotherapies and advanced cell manufacturing technologies continue to evolve, the market presents ample opportunities for contract manufacturers to expand their expertise and cater to the increasing demand for high-quality stem cell products.

Market Segmentation Analysis:

The Canada stem cell contract manufacturing market is segmented by various parameters, reflecting the diverse needs and capabilities within the industry:

By Scale of Operation: The commercial segment focuses on large-scale production of stem cell therapies for market distribution, accounting for a significant portion of the market share due to the increasing number of approved stem cell therapies and the growing demand for regenerative medicine solutions. The clinical segment involves the production of stem cells for clinical trials, which is crucial for advancing stem cell therapies through regulatory approval processes. It holds a notable market share as Canada hosts numerous clinical trials in stem cell research. Preclinical manufacturing supports early-stage research and development, focusing on the production of stem cells for experimental purposes. This segment is smaller but essential for the initial stages of therapy development.

By Size of Contract Manufacturer: Large and very large manufacturers have extensive capabilities and infrastructure, often serving multiple clients with high-volume production needs. They dominate the market share due to their capacity to handle large-scale operations. Mid-sized manufacturers offer a balance between flexibility and capacity, catering to both small and large clients. They hold a significant share, providing specialized services tailored to specific client needs. Small-sized entities focus on niche markets or specific therapies, offering personalized services. Their market share is smaller but growing, driven by the need for specialized manufacturing capabilities.

By Source of Stem Cells: Allogenic stem cells, sourced from donors, are increasingly popular due to their scalability and potential for off-the-shelf treatments. This segment is expanding rapidly. Autologous stem cells, derived from the patient themselves, ensure compatibility but require individual processing. This segment, while smaller, is critical for personalized medicine applications.

By Type of Stem Cells: Adult Stem Cells (ASCs) are the most commonly used due to their availability and lower ethical concerns compared to embryonic stem cells. They hold a significant market share. Human Embryonic Stem Cells (HESCs), although ethically controversial, offer unique potential for regenerative medicine. Their market share is smaller but growing with advancements in research. Induced Pluripotent Stem Cells (iPSCs), reprogrammed from adult cells, are gaining traction for their potential in personalized medicine and disease modeling, with an increasing market share.

By End-user: Biopharmaceutical companies are the primary end-users, leveraging stem cell manufacturing for drug development and therapy production. They hold the largest market share due to their extensive R&D activities. Research institutes utilize stem cell manufacturing for basic research, clinical trials, and educational purposes. Their market share is significant, driven by government funding and collaborative research initiatives. Other entities, including startups and private clinics, are also engaging in stem cell manufacturing for niche applications. Their market share is smaller but growing with the democratization of stem cell technology.

Segmentation:

By Scale of Operation

  • Commercial
  • Clinical
  • Preclinical

By Size of Contract Manufacturer

  • Large/Very Large
  • Mid-sized
  • Small-sized

By Source of Stem Cells

  • Allogenic
  • Autologous

By Type of Stem Cells

  • Adult Stem Cells (ASCs)
  • Human Embryonic Stem Cells (HESCs)
  • Induced Pluripotent Stem Cells (iPSCs)

By End-user

  • Biopharmaceutical companies
  • Research Institutes
  • Others

Regional Analysis:

The Canada Stem Cell Contract Manufacturing Market is experiencing steady growth, driven by increasing research and development in regenerative medicine, advancements in stem cell technologies, and an expanding focus on personalized healthcare solutions. The market is characterized by a diverse range of applications, including cell therapies, regenerative medicine, and drug discovery. The rising demand for high-quality stem cell manufacturing services is further propelled by ongoing developments in the biotechnology and pharmaceutical sectors.

Eastern Canada

Eastern Canada, encompassing provinces such as Ontario, Quebec, and the Atlantic regions, holds a substantial share of the market. Ontario, in particular, leads the region with a market share of approximately 40% in 2024. The presence of several renowned research institutions and universities, such as the University of Toronto and McGill University, has contributed to a robust stem cell research ecosystem. Additionally, Ontario’s strong biotechnology sector, coupled with government funding and support for stem cell research, strengthens its position in the contract manufacturing market. Quebec, with a growing number of biotech startups, also plays a key role in advancing stem cell therapies. Eastern Canada is expected to continue driving innovation, especially in the areas of stem cell-based therapies for regenerative medicine.

Western Canada

Western Canada, including provinces like British Columbia, Alberta, and Saskatchewan, represents a rapidly growing segment of the market, accounting for approximately 30% of the market share in 2024. British Columbia is home to a vibrant biotechnology and life sciences sector, with Vancouver emerging as a hub for stem cell research and commercialization. Alberta also shows significant potential due to its increasing investments in biotechnology and regenerative medicine. Western Canada is becoming a crucial player in the stem cell contract manufacturing space, thanks to expanding research initiatives, collaboration between academic institutions and industry players, and favorable government policies supporting biotech innovation.

Central Canada

Central Canada, primarily represented by the province of Manitoba, accounts for 15% of the market share in 2024. The region has witnessed growth in stem cell research and manufacturing driven by increasing collaboration between hospitals, universities, and private sector companies. With significant government funding and the establishment of research partnerships, Central Canada is emerging as a significant player in the stem cell market, focusing on specialized therapies and cellular treatments for a variety of medical conditions.

Northern and Other Regions

The northern and smaller regions of Canada, including territories like Yukon, Northwest Territories, and Nunavut, contribute a smaller portion to the overall market, collectively holding about 15% of the market share in 2024. While these regions are not as heavily involved in stem cell contract manufacturing as their southern counterparts, they still contribute to the broader Canadian ecosystem through research collaborations and increasing healthcare investments.

Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!

Key Player Analysis:

  •        WuXi AppTec
  •          Boehringer Ingelheim
  •          Catalent Inc.
  •         FUJIFILM Diosynth Biotechnologies
  •         Samsung Biologics
  •          Thermo Fisher Scientific Inc.
  •         Cytovance Biologics
  •         Cytiva

Competitive Analysis:

The Canada stem cell contract manufacturing market is characterized by a dynamic competitive landscape, with several key players vying for market share. OmniaBio has recently opened a state-of-the-art commercial manufacturing facility in Hamilton, Ontario, marking a significant milestone in the Canadian biotechnology landscape. This facility, the largest of its kind in Canada, is dedicated to the production of cell and gene therapies (CGT), enhancing access to life-saving treatments for patients. STEMCELL Technologies has also made notable strides through its partnership with WiCell, launching human pluripotent stem cell characterization and banking services, which underscores the industry’s focus on standardization and quality control. The market is witnessing a trend towards consolidation, with large multinational corporations like Thermo Fisher Scientific, Merck Group, and Lonza Group leveraging their extensive research capabilities and robust distribution networks to maintain significant market share. These companies are investing heavily in research and development, focusing on advanced cell culture media, reagents, and automated manufacturing systems. Strategic collaborations with research institutions and biotechnology firms are common, aiming to strengthen technological capabilities and expand market reach. For instance, collaboration in the Canada stem cell contract manufacturing market is the partnership between The Ottawa Hospital, the University of Alberta, and BioCanRx. This collaboration aims to enhance Canada’s biomanufacturing capacity by creating a full-service, end-to-end biomanufacturing solution for academic and industrial clients. The competitive environment is further intensified by the presence of regional players focusing on specific geographic markets or specialized product segments, contributing to a moderately to highly consolidated market. The industry’s emphasis on operational excellence, geographic expansion, and the automation and digitalization of manufacturing processes reflects the competitive drive to improve efficiency and maintain consistent product quality.

Recent Developments:

  • In February 2024, Samsung Biologics partnered with LegoChem Biosciences for the development and manufacturing of ADCs. According to the partnership terms, the company would offer antibody development & drug substance manufacturing services to LegoChem Biosciences as part of its ADC program designed to treat solid tumors.
  • In May 2024, WuXi AppTec, Inc. announced its expansion by opening its new R&D and manufacturing facility in Singapore. This new facility provides API R&D and manufacturing services for peptides, small molecules, complex synthetic conjugates, & oligonucleotides.
  • In October 2023, Lonza announced the introduction of a new filling line specifically designed for the commercial supply of Antibody-Drug Conjugates (ADCs) for a dedicated customer. This state-of-the-art cGMP filling line, located at Lonza’s Stein (CH) site, is equipped to handle and fill bioconjugates for commercial distribution.

Market Concentration & Characteristics:

The Canada stem cell contract manufacturing market exhibits a moderately to highly consolidated landscape, characterized by the presence of both large multinational corporations and regional players. Key players like Thermo Fisher Scientific, Merck Group, and Lonza Group leverage their extensive research capabilities and robust distribution networks to maintain significant market share. These companies are investing heavily in research and development, focusing on advanced cell culture media, reagents, and automated manufacturing systems. Strategic collaborations with research institutions and biotechnology firms are common, aiming to strengthen technological capabilities and expand market reach. The market is witnessing a trend towards consolidation, with large players acquiring smaller entities to broaden their product portfolios and geographic presence. This competitive environment is further intensified by regional players focusing on specific geographic markets or specialized product segments, contributing to the market’s dynamic nature.

Report Coverage:

The research report offers an in-depth analysis based on By Scale of Operation, By Size of Contract Manufacturer, By Source of Stem Cells, By Type of Stem Cells and By End-user. It details leading market players, providing an overview of their business, product offerings, investments, revenue streams, and key applications. Additionally, the report includes insights into the competitive environment, SWOT analysis, current market trends, as well as the primary drivers and constraints. Furthermore, it discusses various factors that have driven market expansion in recent years. The report also explores market dynamics, regulatory scenarios, and technological advancements that are shaping the industry. It assesses the impact of external factors and global economic changes on market growth. Lastly, it provides strategic recommendations for new entrants and established companies to navigate the complexities of the market.

Future Outlook:

  • The Canada stem cell contract manufacturing market is poised for significant growth, driven by increasing demand for personalized medicine and regenerative therapies.
  • Increasing investments in stem cell research, particularly from government initiatives like the Stem Cell Network’s IGNITE 2022-2025 plan, will bolster the market’s expansion.
  • The market will benefit from the rising prevalence of chronic diseases, necessitating advanced stem cell therapies for treatment.
  • Collaborations between research institutions and biotechnology companies will continue to drive innovation in stem cell manufacturing processes and applications.
  • The focus on automation and closed system process technologies will enhance the efficiency and scalability of stem cell production, meeting the growing clinical demand.
  • Canada’s advanced healthcare infrastructure and regulatory environment will support the market’s growth, ensuring high-quality manufacturing standards.
  • The market will see an increase in the establishment of specialized facilities and infrastructure to support stem cell manufacturing, reflecting the industry’s maturation.
  • The integration of continuous manufacturing with digitization will present lucrative opportunities for stem cell therapy commercialization.
  • The market will witness a trend towards consolidation, with large multinational corporations like Thermo Fisher Scientific and Merck Group expanding their presence through acquisitions and partnerships.
  • The growing awareness and acceptance of stem cell therapies within the medical community will further propel market growth, with Canada’s market share in North America expected to remain significant.

CHAPTER NO. 1 : INTRODUCTION 19

1.1. Report Description 19

Purpose of the Report 19

USP & Key Offerings 19

1.2. Key Benefits for Stakeholders 19

1.3. Target Audience 20

1.4. Report Scope 20

CHAPTER NO. 2 : EXECUTIVE SUMMARY 21

2.1. Canada Stem Cell Contract Manufacturing Market Snapshot 21

2.2. Canada Stem Cell Contract Manufacturing Market, 2018 – 2032 (USD Million) 22

CHAPTER NO. 3 : CANADA STEM CELL CONTRACT MANUFACTURING MARKET – INDUSTRY ANALYSIS 23

3.1. Introduction 23

3.2. Market Drivers 24

3.3. Increasing interest in regenerative medicine 24

3.4. Demand for Specialized Manufacturing Expertise 25

3.5. Market Restraints 26

3.6. Regulatory Complexity 26

3.7. Market Opportunities 27

3.8. Market Opportunity Analysis 27

3.9. Porter’s Five Forces Analysis 28

CHAPTER NO. 4 : ANALYSIS COMPETITIVE LANDSCAPE 29

4.1. Company Market Share Analysis – 2023 29

4.1.1. Canada Stem Cell Contract Manufacturing Market: Company Market Share, by Volume, 2023 29

4.1.2. Canada Stem Cell Contract Manufacturing Market: Company Market Share, by Revenue, 2023 30

4.1.3. Canada Stem Cell Contract Manufacturing Market: Top 6 Company Market Share, by Revenue, 2023 30

4.1.4. Canada Stem Cell Contract Manufacturing Market: Top 3 Company Market Share, by Revenue, 2023 31

4.2. Canada Stem Cell Contract Manufacturing Market Company Revenue Market Share, 2023 32

4.3. Company Assessment Metrics, 2023 33

4.3.1. Stars 33

4.3.2. Emerging Leaders 33

4.3.3. Pervasive Players 33

4.3.4. Participants 33

4.4. Start-ups /SMEs Assessment Metrics, 2023 33

4.4.1. Progressive Companies 33

4.4.2. Responsive Companies 33

4.4.3. Dynamic Companies 33

4.4.4. Starting Blocks 33

4.5. Strategic Developments 34

4.5.1. Acquisitions & Mergers 34

New Product Launch 34

Regional Expansion 34

4.6. Key Players Product Matrix 35

CHAPTER NO. 5 : PESTEL & ADJACENT MARKET ANALYSIS 36

5.1. PESTEL 36

5.1.1. Political Factors 36

5.1.2. Economic Factors 36

5.1.3. Social Factors 36

5.1.4. Technological Factors 36

5.1.5. Environmental Factors 36

5.1.6. Legal Factors 36

5.2. Adjacent Market Analysis 36

CHAPTER NO. 6 : CANADA STEM CELL CONTRACT MANUFACTURING MARKET – BY SCALE OF OPERATION SEGMENT ANALYSIS 37

6.1. Canada Stem Cell Contract Manufacturing Market Overview, by Scale of Operation Segment 37

6.1.1. Canada Stem Cell Contract Manufacturing Market Revenue Share, By Scale of Operation, 2023 & 2032 38

6.1.2. Canada Stem Cell Contract Manufacturing Market Attractiveness Analysis, By Scale of Operation 39

6.1.3. Incremental Revenue Growth Opportunity, by Scale of Operation, 2024 – 2032 39

6.1.4. Canada Stem Cell Contract Manufacturing Market Revenue, By Scale of Operation, 2018, 2023, 2027 & 2032 40

6.2. Commercial 41

6.3. Clinical 42

6.4. Preclinical 43

CHAPTER NO. 7 : CANADA STEM CELL CONTRACT MANUFACTURING MARKET – BY SIZE OF CONTRACT MANUFACTURER SEGMENT ANALYSIS 44

7.1. Canada Stem Cell Contract Manufacturing Market Overview, by Size of Contract Manufacturer Segment 44

7.1.1. Canada Stem Cell Contract Manufacturing Market Revenue Share, By Size of Contract Manufacturer, 2023 & 2032 45

7.1.2. Canada Stem Cell Contract Manufacturing Market Attractiveness Analysis, By Size of Contract Manufacturer 46

7.1.3. Incremental Revenue Growth Opportunity, by Size of Contract Manufacturer, 2024 – 2032 46

7.1.4. Canada Stem Cell Contract Manufacturing Market Revenue, By Size of Contract Manufacturer, 2018, 2023, 2027 & 2032 47

7.2. Large/Very Large 48

7.3. Mid-sized 49

7.4. Small-sized 50

CHAPTER NO. 8 : CANADA STEM CELL CONTRACT MANUFACTURING MARKET – BY END-USER SEGMENT ANALYSIS 51

8.1. Canada Stem Cell Contract Manufacturing Market Overview, by End-user Segment 51

8.1.1. Canada Stem Cell Contract Manufacturing Market Revenue Share, By End-user, 2023 & 2032 52

8.1.2. Canada Stem Cell Contract Manufacturing Market Attractiveness Analysis, By End-user 53

8.1.3. Incremental Revenue Growth Opportunity, by End-user, 2024 – 2032 53

8.1.4. Canada Stem Cell Contract Manufacturing Market Revenue, By End-user, 2018, 2023, 2027 & 2032 54

8.2. Biopharmaceutical companies 55

8.3. Research Institutes 56

8.4. Others 57

CHAPTER NO. 9 : CANADA STEM CELL CONTRACT MANUFACTURING MARKET – BY SOURCE OF STEM CELLS SEGMENT ANALYSIS 58

9.1. Canada Stem Cell Contract Manufacturing Market Overview, by Source of Stem Cells Segment 58

9.1.1. Canada Stem Cell Contract Manufacturing Market Revenue Share, By Source of Stem Cells, 2023 & 2032 59

9.1.2. Canada Stem Cell Contract Manufacturing Market Attractiveness Analysis, By Source of Stem Cells 60

9.1.3. Incremental Revenue Growth Opportunity, by Source of Stem Cells, 2024 – 2032 60

9.1.4. Canada Stem Cell Contract Manufacturing Market Revenue, By Source of Stem Cells, 2018, 2023, 2027 & 2032 61

9.2. Allogenic 62

9.3. Autologous 63

CHAPTER NO. 10 : CANADA STEM CELL CONTRACT MANUFACTURING MARKET – BY TYPE OF STEM CELLS SEGMENT ANALYSIS 64

10.1. Canada Stem Cell Contract Manufacturing Market Overview, by Type of Stem Cells Segment 64

10.1.1. Canada Stem Cell Contract Manufacturing Market Revenue Share, By Type of Stem Cells, 2023 & 2032 65

10.1.2. Canada Stem Cell Contract Manufacturing Market Attractiveness Analysis, By Type of Stem Cells 66

10.1.3. Incremental Revenue Growth Opportunity, by Type of Stem Cells, 2024 – 2032 66

10.1.4. Canada Stem Cell Contract Manufacturing Market Revenue, By Type of Stem Cells, 2018, 2023, 2027 & 2032 67

10.2. Adult Stem Cells (ASCs) 68

10.3. Human Embryonic Stem Cells (HESCs) 69

10.4. Induced Pluripotent Stem Cells (iPSCs) 70

CHAPTER NO. 11 : CANADA STEM CELL CONTRACT MANUFACTURING MARKET – ANALYSIS 71

11.1.1. Canada Stem Cell Contract Manufacturing Market Revenue, By Scale of Operation, 2018 – 2023 (USD Million) 71

11.1.2. Canada Stem Cell Contract Manufacturing Market Revenue, By Size of Contract Manufacturer, 2018 – 2023 (USD Million) 72

11.1.3. Canada Stem Cell Contract Manufacturing Market Revenue, By End-user, 2018 – 2023 (USD Million) 73

11.1.4. Canada Stem Cell Contract Manufacturing Market Revenue, By Source of Stem Cells, 2018 – 2023 (USD Million) 74

11.1.5. Canada Stem Cell Contract Manufacturing Market Revenue, By Type of Stem Cells, 2018 – 2023 (USD Million) 75

CHAPTER NO. 12 : COMPANY PROFILES 76

12.1. Lonza Group 76

12.1.1. Company Overview 76

12.1.2. Product Portfolio 76

12.1.3. Swot Analysis 76

12.1.4. Business Strategy 77

12.1.5. Financial Overview 77

12.2. WuXi AppTec 78

12.3. Boehringer Ingelheim 78

12.4. Catalent Inc. 78

12.5. FUJIFILM Diosynth Biotechnologies 78

12.6. Samsung Biologics 78

12.7. Thermo Fisher Scientific Inc. 78

12.8. Cytovance Biologics 78

12.9. Cytiva 78

List of Figures

FIG NO. 1. Canada Stem Cell Contract Manufacturing Market Revenue, 2018 – 2032 (USD Million) 22

FIG NO. 2. Porter’s Five Forces Analysis for Canada Stem Cell Contract Manufacturing Market 28

FIG NO. 3. Company Share Analysis, 2023 29

FIG NO. 4. Company Share Analysis, 2023 30

FIG NO. 5. Company Share Analysis, 2023 30

FIG NO. 6. Company Share Analysis, 2023 31

FIG NO. 7. Canada Stem Cell Contract Manufacturing Market – Company Revenue Market Share, 2023 32

FIG NO. 8. Canada Stem Cell Contract Manufacturing Market Revenue Share, By Scale of Operation, 2023 & 2032 38

FIG NO. 9. Market Attractiveness Analysis, By Scale of Operation 39

FIG NO. 10. Incremental Revenue Growth Opportunity by Scale of Operation, 2024 – 2032 39

FIG NO. 11. Canada Stem Cell Contract Manufacturing Market Revenue, By Scale of Operation, 2018, 2023, 2027 & 2032 40

FIG NO. 12. Canada Stem Cell Contract Manufacturing Market for Commercial, Revenue (USD Million) 2018 – 2032 41

FIG NO. 13. Canada Stem Cell Contract Manufacturing Market for Clinical, Revenue (USD Million) 2018 – 2032 42

FIG NO. 14. Canada Stem Cell Contract Manufacturing Market for Preclinical, Revenue (USD Million) 2018 – 2032 43

FIG NO. 15. Canada Stem Cell Contract Manufacturing Market Revenue Share, By Size of Contract Manufacturer, 2023 & 2032 45

FIG NO. 16. Market Attractiveness Analysis, By Size of Contract Manufacturer 46

FIG NO. 17. Incremental Revenue Growth Opportunity by Size of Contract Manufacturer, 2024 – 2032 46

FIG NO. 18. Canada Stem Cell Contract Manufacturing Market Revenue, By Size of Contract Manufacturer, 2018, 2023, 2027 & 2032 47

FIG NO. 19. Canada Stem Cell Contract Manufacturing Market for Large/Very Large, Revenue (USD Million) 2018 – 2032 48

FIG NO. 20. Canada Stem Cell Contract Manufacturing Market for Mid-sized, Revenue (USD Million) 2018 – 2032 49

FIG NO. 21. Canada Stem Cell Contract Manufacturing Market for Small-sized, Revenue (USD Million) 2018 – 2032 50

FIG NO. 22. Canada Stem Cell Contract Manufacturing Market Revenue Share, By End-user, 2023 & 2032 52

FIG NO. 23. Market Attractiveness Analysis, By End-user 53

FIG NO. 24. Incremental Revenue Growth Opportunity by End-user, 2024 – 2032 53

FIG NO. 25. Canada Stem Cell Contract Manufacturing Market Revenue, By End-user, 2018, 2023, 2027 & 2032 54

FIG NO. 26. Canada Stem Cell Contract Manufacturing Market for Biopharmaceutical companies, Revenue (USD Million) 2018 – 2032 55

FIG NO. 27. Canada Stem Cell Contract Manufacturing Market for Research Institutes, Revenue (USD Million) 2018 – 2032 56

FIG NO. 28. Canada Stem Cell Contract Manufacturing Market for Others, Revenue (USD Million) 2018 – 2032 57

FIG NO. 29. Canada Stem Cell Contract Manufacturing Market Revenue Share, By Source of Stem Cells, 2023 & 2032 59

FIG NO. 30. Market Attractiveness Analysis, By Source of Stem Cells 60

FIG NO. 31. Incremental Revenue Growth Opportunity by Source of Stem Cells, 2024 – 2032 60

FIG NO. 32. Canada Stem Cell Contract Manufacturing Market Revenue, By Source of Stem Cells, 2018, 2023, 2027 & 2032 61

FIG NO. 33. Canada Stem Cell Contract Manufacturing Market for Allogenic, Revenue (USD Million) 2018 – 2032 62

FIG NO. 34. Canada Stem Cell Contract Manufacturing Market for Autologous, Revenue (USD Million) 2018 – 2032 63

FIG NO. 35. Canada Stem Cell Contract Manufacturing Market Revenue Share, By Type of Stem Cells, 2023 & 2032 65

FIG NO. 36. Market Attractiveness Analysis, By Type of Stem Cells 66

FIG NO. 37. Incremental Revenue Growth Opportunity by Type of Stem Cells, 2024 – 2032 66

FIG NO. 38. Canada Stem Cell Contract Manufacturing Market Revenue, By Type of Stem Cells, 2018, 2023, 2027 & 2032 67

FIG NO. 39. Canada Stem Cell Contract Manufacturing Market for Adult Stem Cells (ASCs), Revenue (USD Million) 2018 – 2032 68

FIG NO. 40. Canada Stem Cell Contract Manufacturing Market for Human Embryonic Stem Cells (HESCs), Revenue (USD Million) 2018 – 2032 69

FIG NO. 41. Canada Stem Cell Contract Manufacturing Market for Induced Pluripotent Stem Cells (iPSCs), Revenue (USD Million) 2018 – 2032 70

List of Tables

TABLE NO. 1. : Canada Stem Cell Contract Manufacturing Market: Snapshot 21

TABLE NO. 2. : Drivers for the Canada Stem Cell Contract Manufacturing Market: Impact Analysis 24

TABLE NO. 3. : Restraints for the Canada Stem Cell Contract Manufacturing Market: Impact Analysis 26

TABLE NO. 4. : Canada Stem Cell Contract Manufacturing Market Revenue, By Scale of Operation, 2018 – 2023 (USD Million) 71

TABLE NO. 5. : Canada Stem Cell Contract Manufacturing Market Revenue, By Scale of Operation, 2024 – 2032 (USD Million) 71

TABLE NO. 6. : Canada Stem Cell Contract Manufacturing Market Revenue, By Size of Contract Manufacturer, 2018 – 2023 (USD Million) 72

TABLE NO. 7. : Canada Stem Cell Contract Manufacturing Market Revenue, By Size of Contract Manufacturer, 2024 – 2032 (USD Million) 72

TABLE NO. 8. : Canada Stem Cell Contract Manufacturing Market Revenue, By End-user, 2018 – 2023 (USD Million) 73

TABLE NO. 9. : Canada Stem Cell Contract Manufacturing Market Revenue, By End-user, 2024 – 2032 (USD Million) 73

TABLE NO. 10. : Canada Stem Cell Contract Manufacturing Market Revenue, By Source of Stem Cells, 2018 – 2023 (USD Million) 74

TABLE NO. 11. : Canada Stem Cell Contract Manufacturing Market Revenue, By Source of Stem Cells, 2024 – 2032 (USD Million) 74

TABLE NO. 12. : Canada Stem Cell Contract Manufacturing Market Revenue, By Type of Stem Cells, 2018 – 2023 (USD Million) 75

TABLE NO. 13. : Canada Stem Cell Contract Manufacturing Market Revenue, By Type of Stem Cells, 2024 – 2032 (USD Million) 75

 

Frequently Asked Questions

What is the projected growth of the Canada Stem Cell Contract Manufacturing Market from 2024 to 2032?

The market is expected to grow from USD 78.86 million in 2024 to an estimated USD 190.17 million by 2032, with a CAGR of 11.63%.

What are the primary drivers of the Canada stem cell contract manufacturing market?

The market is driven by the increasing prevalence of chronic diseases, the potential of stem cells in regenerative medicine, the focus on personalized medicine, and the rising number of partnerships between contract manufacturers and biotechnology companies.

What are the key regions in Canada for stem cell contract manufacturing?

Toronto, Montreal, and Vancouver are key hubs for stem cell research institutes, pharmaceutical companies, and contract manufacturing organizations (CMOs).

What are the main challenges faced by the Canada stem cell contract manufacturing market?

The primary challenges include high production costs and the complexity of stem cell therapy manufacturing, which can hinder market growth and scalability.

Canada Data Center Maintenance and Support Services Market

Published:
Report ID: 75529

Canada Processed Beef Product Market

Published:
Report ID: 75170

Canada High-End Beef Market

Published:
Report ID: 74872

Canada AC-DC Power Supply in Data Center Market

Published:
Report ID: 74821

Canada Large Language Model Powered Tools Market

Published:
Report ID: 74801

Canada Data Center Filters Market

Published:
Report ID: 74730

Canada Interior Design Market

Published:
Report ID: 73839

Canada Data Center Uninterruptable Power Supply (UPS) Market

Published:
Report ID: 72940

Canada Data Center Processor Market

Published:
Report ID: 72904

MEA Biologics and Biosimilars Market

Published:
Report ID: 75183

Cell Regeneration Medicine Market

Published:
Report ID: 74708

Antisense Oligonucleotides Market

Published:
Report ID: 74051

Cell Culture Sampling Devices Market

Published:
Report ID: 73920

Cell and Gene Therapy Manufacturing Market

Published:
Report ID: 73917

Capsule Endoscope and Workstation Market

Published:
Report ID: 20339

Australia Occupational Health Market

Published:
Report ID: 61938

Rapid Microbiology Testing Market

Published:
Report ID: 73613

UK Stem Cell Contract Manufacturing Market

Published:
Report ID: 72565

U.S. Stem Cell Contract Manufacturing Market

Published:
Report ID: 72553

Middle East Stem Cell Contract Manufacturing Market

Published:
Report ID: 72494

Mexico Stem Cell Contract Manufacturing Market

Published:
Report ID: 72483

Purchase Options

The report comes as a view-only PDF document, optimized for individual clients. This version is recommended for personal digital use and does not allow printing.
$2699

To meet the needs of modern corporate teams, our report comes in two formats: a printable PDF and a data-rich Excel sheet. This package is optimized for internal analysis and multi-location access, making it an excellent choice for organizations with distributed workforce.
$3699

The report will be delivered in printable PDF format along with the report’s data Excel sheet. This license offers 100 Free Analyst hours where the client can utilize Credence Research Inc.’s research team. It is highly recommended for organizations seeking to execute short, customized research projects related to the scope of the purchased report.
$5699

Smallform of Sample request

Have a question?

User Profile

Don’t settle for less – trust Mitul to help you find the best solution.

Report delivery within 24 to 48 hours

– Other Info –

What people say?-

User Review

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –

Phone

+91 6232 49 3207


support

24/7 Research Support


sales@credenceresearch.com

– Research Methodology –

Going beyond the basics: advanced techniques in research methodology

– Trusted By –

Pepshi, LG, Nestle
Motorola, Honeywell, Johnson and johnson
LG Chem, SIEMENS, Pfizer
Unilever, Samsonite, QIAGEN